Cargando…
Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn’s disease
We report a case of concurrent development of active pulmonary tuberculosis and invasive pulmonary aspergillosis (IPA) in a patient who received therapy with infliximab for Crohn’s disease. He has been treated with antitubercular therapy and liposomal amphotericin B for 8 weeks. His clinical course...
Autores principales: | Buonomo, Antonio Riccardo, Viceconte, Giulio, Compare, Debora, Vargas, Maria, Iacovazzo, Carmine, Zappulo, Emanuela, Nardone, Gerardo, Servillo, Giuseppe, Borgia, Guglielmo, Gentile, Ivan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667483/ https://www.ncbi.nlm.nih.gov/pubmed/31384555 http://dx.doi.org/10.1016/j.idcr.2019.e00537 |
Ejemplares similares
-
Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient
por: Vargas, Maria, et al.
Publicado: (2019) -
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
por: Gentile, Ivan, et al.
Publicado: (2014) -
Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves
por: Cattaneo, Letizia, et al.
Publicado: (2023) -
Pneumocystis jirovecii pneumonia in COVID-19: an overlooked clinical entity—Response to “Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19”
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2021) -
Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
por: Moriello, Nicola Schiano, et al.
Publicado: (2023)